Dr. Reddy’s Laboratories presents preclinical data at SITC 2020 demonstrating significant improvement in tumor growth inhibition and overall survival through a combination of E7777 (denileukin diftitox) and an immune checkpoint inhibitor

On November 10, 2020 Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy’s") reported a preclinical data presentation for E7777 (denileukin diftitox), its engineered IL-2-diphtheria toxin fusion protein, at the The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 35th Anniversary Annual Meeting, being held virtually (Press release, Dr Reddy’s, NOV 10, 2020, View Source [SID1234570477]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Anil Namboodiripad, Senior Vice President and Head of Dr. Reddy’s Proprietary Products Division stated, "We are encouraged that in addition to the clinically demonstrated safety and activity of denileukin diftitox in patients with cutaneous T cell lymphoma, these new syngeneic mouse model studies show that E7777 also shows promising activity as a potential immunotherapy agent for treatment of solid tumors. Combination of E7777 with an anti-PD-1 agent provided clear benefit both in terms of tumor growth control, and a highly significant improvement in overall survival. We look forward to conducting clinical trials to further explore this combination."

Key findings from the presentation are included below.

Title: E7777 (Denileukin Diftitox) Enhances Anti-Tumor Activity and Significantly Extends Survival Benefit of Anti-PD-1 in Syngeneic Solid Tumor Models

 E7777 administered as monotherapy inhibited tumor growth with activity comparable to anti-PD1 monotherapy in syngeneic murine tumor models
 Combination of E7777 and anti-PD-1 inhibited tumor growth substantially better than monotherapy treatments Administration of E7777 and anti-PD-1 for a limited treatment period led to highly significant improvements in long-term survival
 Combination of E7777 and anti-PD-1 was administration schedule independent